APA (7th ed.) Citation

Modest, D., Neumann, U., & Pratschke, J. (2017). FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity? European Journal of Cancer, 73, 71. https://doi.org/10.1016/j.ejca.2016.12.005

Chicago Style (17th ed.) Citation

Modest, D.P, U.P Neumann, and J. Pratschke. "FOLFOXIRI Plus Bevacizumab as Conversion-therapy for Liver Metastases in Colorectal Cancer: A Necessity?" European Journal of Cancer 73 (2017): 71. https://doi.org/10.1016/j.ejca.2016.12.005.

MLA (9th ed.) Citation

Modest, D.P, et al. "FOLFOXIRI Plus Bevacizumab as Conversion-therapy for Liver Metastases in Colorectal Cancer: A Necessity?" European Journal of Cancer, vol. 73, 2017, p. 71, https://doi.org/10.1016/j.ejca.2016.12.005.